Pitt H A, McFadden D W, Gadacz T R
Am J Surg. 1987 Feb;153(2):233-46. doi: 10.1016/0002-9610(87)90822-1.
Numerous methods are presently available for gallstone dissolution, including oral bile salts; cholesterol solvents such as mono-octanoin and methyl tert-butyl ether; calcium or pigment solvents such as EDTA and polysorbate; mechanical extraction techniques through a T-tube tract or after endoscopic sphincterotomy; or fragmentation methods such as ultrasonography or electrohydraulic lithotripsy, lasers, and extracorporeal shock waves. Which, if any, of these methods will be appropriate for an individual patient depends on the type of stones, whether they are in the gallbladder or bile ducts, whether access to the biliary tree is available, the patient's age and general medical condition, and the availability of expert radiologists, endoscopists, and newer equipment. In the United States, the only available oral bile salt for cholesterol gallstone dissolution is chenodeoxycholate. Ursodeoxycholate, which is more rapid and less toxic, has not been approved by the Federal Drug Administration. These agents are most effective in thin women with small, floating, radiolucent cholesterol gallstones in a functioning gallbladder. Only about half of this small subset of patients, however, will experience partial or complete dissolution of stones in 6 to 12 months. Moreover, recurrence is very likely, and the potential toxicity of long-term therapy is unknown. Thus, for most patients, cholecystectomy remains the most cost-effective and, perhaps, safest option. Intragallbladder instillation of methyl tert-butyl ether and extracorporeal shock wave therapy are also likely to be applicable to only small subsets of patients and to be associated with high recurrence rates. In patients with retained ductal cholesterol stones and access to the biliary tree, mono-octanoin therapy is advantageous in that it can be begun as soon as cholangiography demonstrates no extravasation. In properly selected patients, a 90 percent success rate with mono-octanoin infusion can be expected within a week. Radiologic or endoscopic extraction techniques require maturation of a relatively straight T-tube tract but are not dependent on the type of stone. In the hands of experts, these techniques are highly successful. In postcholecystectomy patients without access to the biliary tree, endoscopic sphincterotomy has become the preferred method of management and can be expected to succeed in more than 90 percent of patients. At this point, the exact role for ultrasonic or electrohydraulic lithotripsy and lasers is unknown. However, these techniques may be applicable in the future in patients with retained bile duct stones in whom extraction and infusion techniques have failed.
目前有多种方法可用于胆结石溶解,包括口服胆盐;胆固醇溶剂,如单辛脂和甲基叔丁基醚;钙或色素溶剂,如乙二胺四乙酸(EDTA)和聚山梨酯;通过T形管通道或在内镜括约肌切开术后进行的机械取石技术;或碎石方法,如超声检查、液电碎石术、激光和体外冲击波碎石术。这些方法中哪一种(如果有的话)适用于个体患者,取决于结石的类型、结石是在胆囊还是胆管中、是否能够进入胆道系统、患者的年龄和一般健康状况,以及是否有专业的放射科医生、内镜医生和更新的设备。在美国,唯一可用于溶解胆固醇结石的口服胆盐是鹅去氧胆酸。熊去氧胆酸溶解速度更快且毒性更小,但尚未获得美国食品药品监督管理局的批准。这些药物对胆囊功能正常、体型瘦、结石小、可漂浮、透X线的胆固醇结石的女性最为有效。然而,在这一小部分患者中,只有约一半的人在6至12个月内会出现结石部分或完全溶解。此外,复发的可能性很大,长期治疗的潜在毒性尚不清楚。因此,对于大多数患者来说,胆囊切除术仍然是最具成本效益且可能是最安全的选择。胆囊内注入甲基叔丁基醚和体外冲击波疗法也可能仅适用于一小部分患者,且复发率较高。对于有残留胆管胆固醇结石且能够进入胆道系统的患者,单辛脂疗法具有优势,因为一旦胆管造影显示无渗漏即可开始治疗。在经过适当选择的患者中,预计单辛脂输注一周内成功率可达90%。放射学或内镜取石技术需要相对笔直的T形管通道成熟,但不依赖于结石类型。在专家手中,这些技术非常成功。对于胆囊切除术后无法进入胆道系统的患者,内镜括约肌切开术已成为首选的治疗方法,预计成功率超过90%。目前,超声或液电碎石术以及激光的确切作用尚不清楚。然而,这些技术未来可能适用于残留胆管结石且取石和注入技术失败的患者。